Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours

Journal of Pathology

Volumn 196, Issue 1, 2002, Pages 1-7

  Esteller, Manel ^a,b   Herman, James G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Cancer; Chromatin; DNA methylation; DNA repair; Epigenetics; Gene expression

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BIOLOGICAL MARKER; BRCA1 PROTEIN; DNA; PROTEIN MLH1; PROTEIN P14; PROTEIN P15; PROTEIN P16;

ANEUPLOIDY; APOPTOSIS; CANCER; CANCER CELL; CANCER RISK; CELL CYCLE; CELL TRANSFORMATION; CHROMATIN; CHROMOSOME ABERRATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA REPAIR; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENE CONTROL; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC DISORDER; GENETIC TRANSCRIPTION; GENOME; GENOME IMPRINTING; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; TUMOR; TUMOR SUPPRESSOR GENE;

CHROMATIN; DNA METHYLATION; DNA, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0036145156     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1024     Document Type: Review

References (70)

1. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells
2. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes
3. CpG-rich islands and the function of DNA methylation
4. The DNA methylation paradox
5. Alterations in DNA methylation: A fundamental aspect of neoplasia
6. DNA methylation is the primary silencing mechanism for a set of germ line- And tumor-specific genes with a CpG-rich promoter
7. DNA methylation and histone acetylation of rat methionine adenosyltransferase 1A and 2A genes is tissue-specific
8. Cytosine methylation and the ecology of intragenomic parasites
9. A gene hypermethylation profile of human cancer
10. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
11. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
12. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene
13. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma
14. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
15. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status
16. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2
17. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer
18. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
19. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
20. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
21. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas
22. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis
23. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability
24. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
25. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis
26. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G : C to A : T transition mutations in p53 in human colorectal tumorigenesis
27. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
28. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
29. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors
30. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells
31. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells
32. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
33. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies
34. Transcriptional silencing of the p73 gene is acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation
35. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
36. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
37. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
38. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome
39. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B
40. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
41. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours
42. 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result
43. DNA hypomethylation in Morris hepatomas
44. DNA hypomethylation and cancer
45. DNA hypomethylation leads to elevated mutation rates
46. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene
47. Undermethylation of specific LINE-1 sequences in human cells producing a LINE-1-encoded protein
48. Differential methylation of human LINE-1 retrotransposons in malignant cells
49. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas
50. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction
51. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
52. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors
53. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia
54. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability
55. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
56. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
57. Mutations truncating the EP300 acetylase in human cancers
58. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
59. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines
60. Proliferation-associated SNF2-like gene (PASG): A SNF2 family member altered in leukemia
61. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation
62. Chromatin remodeling and leukemia: New therapeutic paradigms
63. Decitabine (5-aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations
64. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome
65. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
66. Molecular detection of tumors cells in bronchoalveolar lavage fluid from patients with early stage lung cancer
67. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence
68. Predicting lung cancer by detecting aberrant promoter methylation in sputum
69. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer
70. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents